Early prednisone therapy in Henoch-Schonlein purpura:: A randomized, double-blind, placebo-controlled trial
Early prednisone therapy in Henoch-Schonlein purpura:: A randomized, double-blind, placebo-controlled trial
复制标题
DOI：
10.1016/j.jpeds.2006.03.024
复制
发表时间：
2006-08-01
影响因子：
5.1
通讯作者：
Nuutinen, Mati
中科院分区：
文献类型：
--
作者：
Ronkainen, Jaana;Koskimies, Olli;Nuutinen, Mati
Objective To evaluate the efficacy of early prednisone therapy in preventing renal and treating extrarenal and renal symptoms in Henoch-Schonlein purpura (HSP) in a placebo-controlled trial.Study design A total of 171 patients (84 treated with prednisone and 87 receiving placebo) were included and followed up for 6 months. The endpoints were renal involvement at 1, 3, and 6 months and healing of extrarenal symptoms. The analyses were performed on an intent-to-treat basis.Results Prednisone (1 mg/kg/day for 2 weeks, with weaning over the subsequent 2 weeks) was effective in reducing the intensity of abdominal pain (pain score, 2.5 vs 4.8; P = .029) and joint pain (4.6 vs 7.3; P = .030). Prednisone did not prevent the development of renal symptoms but was effective in treating them; renal symptoms resolved in 61% of the prednisone patients after treatment, compared with 34% of the placebo patients (difference = 27%; 95% confidence interval = 3% to 47%; P = .024).Conclusions The general use of prednisone in HSP is not supported, but patients with disturbing symptoms may benefit from early treatment, because prednisone reduces extrarenal symptoms and is effective in altering (but not preventing) the course of renal involvement.
